Full-Time

Portfolio & Program Management Associate Director

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

No salary listed

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid role: 3 days in office; can work remotely up to two days per week.

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Risk Management
Requirements
  • Breadth of knowledge of project and portfolio management principles, best practices, tools, technology and methods
  • Excellent written and oral communication skills, including well-developed presentation skills
  • Pharmaceutical drug discovery and development specialized knowledge across multiple disciplines
  • Organizational skills and an ability to manage multiple priorities
  • Strong collaboration skills to effectively interact with internal or external stakeholders at all levels in the organization
  • General business management knowledge to assess the impact of project decisions on financial and corporate objectives
  • Typically requires a Bachelor’s degree in Life Sciences or a relevant field
  • Typically requires 8 years of experience, or the equivalent combination of education and experience
  • Experience within the Life Sciences industry or similar
Responsibilities
  • Oversee integrated project planning processes for one or more teams including scheduling, risk management, communication plans and reporting
  • Oversee completion of project team deliverables and contribute to content development, when appropriate
  • Independently facilitate cross-functional team discussions and drive the team toward decisions
  • Partner with team lead(s) to set strategy, goals and milestones
  • Proactively identify roadblocks and/or constraints impacting project execution
  • With support, determine approach and stakeholders for cross-functional decision-making and issue resolution
  • With support, establish project team operating norms and measure performance
  • Provide active meeting management by capturing minutes and tracking action items, when required
  • Apply professional experience to mentor junior PPM staff
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.